Home › Companies › Spyre Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Spyre Therapeutics, Inc.’s Form 8-K, filed May 29, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 27, 2026: 6 items on Spyre Therapeutics, Inc.’s Form 8-K, filed May 29, 2026: 3 approved · 3 passed (calculated).
Notable dissent: 1 director (14.9% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Tang Capital (13F, 2.0%, as of September 30, 2026)
Explore Spyre Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Spyre Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mark McKenna | 65,608,709 | -- | -- | 1,329,489 | 1,500,346 | 98% | Passed (calculated) | — |
| Elect Director: Cameron Turtle, D. Phil. | 66,176,245 | -- | -- | 761,953 | 1,500,346 | 99% | Passed (calculated) | — |
| Elect Director: Laurie Stelzer | 56,954,664 | -- | -- | 9,983,534 | 1,500,346 | 85% | Passed (calculated) | — |
| 2. On a non-binding, advisory basis, the compensation of the Company's named executive officers | 62,075,459 | 4,760,373 | 102,366 | -- | 1,500,346 | 93% | Approved | — |
| 3. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 | 68,430,566 | 670 | 7,308 | -- | 0 | 99.9% | Approved | — |
| 4. Company's AR ESPP | 66,885,864 | 45,542 | 6,792 | -- | 1,500,346 | 99.9% | Approved | — |
Source: Spyre Therapeutics, Inc., Form 8-K, filed with the SEC on May 29, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
220 asset managers disclosed a vote on at least one Spyre Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Spyre Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 7 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Cameron Turtle, D.Phil.
Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Cameron Turtle, D. Phil.”): 66,176,245 for, 761,953 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,604,700 | 0 | 1 | 0 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 658,596 | 0 | 0 | 0 | For |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 414,759 | 0 | 0 | 0 | For |
| Victory Capital | 326,801 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 65,274 | 0 | 0 | 252,945 | Mixed |
| First Trust | 178,135 | 0 | 0 | 0 | For |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 4,299 | 0 | 0 | 155,168 | Withhold |
| Equitable | 157,755 | 0 | 0 | 0 | For |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 82,062 | 0 | 0 | 0 | For |
| Brighthouse | 76,036 | 0 | 0 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 67,170 | 0 | 0 | 0 | For |
| John Hancock | 60,959 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,674 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,311 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 43,636 | 0 | 0 | 0 | For |
Fund voting reports, all 67 managers: 23,088,662 for, 411,671 withheld, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 1,456,231 for.
Combines 7 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Laurie Stelzer
Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Laurie Stelzer”): 56,954,664 for, 9,983,534 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,602,011 | 0 | 15 | 2,674 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 1,384 | 0 | 0 | 657,212 | Withhold |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 414,759 | Withhold |
| Victory Capital | 0 | 0 | 0 | 326,801 | Withhold |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 318,219 | Withhold |
| First Trust | 0 | 0 | 0 | 178,135 | Withhold |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 159,467 | Withhold |
| Equitable | 112,825 | 0 | 0 | 44,930 | Mixed |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 82,062 | 0 | Abstain |
| Brighthouse | 53,625 | 0 | 0 | 22,411 | Mixed |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 67,170 | 0 | Abstain |
| John Hancock | 42,692 | 0 | 18,267 | 0 | Mixed |
| Lincoln Financial | 7,274 | 0 | 0 | 45,400 | Mixed |
| Columbia Threadneedle | 0 | 0 | 0 | 49,311 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 43,636 | Withhold |
Fund voting reports, all 67 managers: 20,823,005 for, 2,495,688 withheld, 181,641 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 1,456,231 for.
Combines 8 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Mark McKenna
Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark McKenna”): 65,608,709 for, 1,329,489 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,604,699 | 0 | 2 | 0 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 658,406 | 0 | 0 | 190 | For |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 414,759 | 0 | 0 | 0 | For |
| Victory Capital | 326,801 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 65,274 | 0 | 0 | 252,945 | Mixed |
| First Trust | 178,135 | 0 | 0 | 0 | For |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 4,299 | 0 | 0 | 155,168 | Withhold |
| Equitable | 112,825 | 0 | 0 | 44,930 | Mixed |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 82,062 | 0 | 0 | 0 | For |
| Brighthouse | 76,036 | 0 | 0 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 67,170 | 0 | 0 | 0 | For |
| John Hancock | 60,959 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,674 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,311 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 43,636 | 0 | 0 | 0 | For |
Fund voting reports, all 67 managers: 23,043,540 for, 456,791 withheld, 2 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 1,456,231 for.
99.9% of fund votes cast · no official result
Description as filed by funds: TO APPROVE THE COMPANY'S AMENDED AND RESTATED 2016 EMPLOYEE STOCK PURCHASE PLAN.
The 68 asset managers below reported 23,490,367 for, 10,401 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,599,112 | 5,589 | 0 | 0 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 657,711 | 885 | 0 | 0 | For |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 414,759 | 0 | 0 | 0 | For |
| Victory Capital | 326,801 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 318,219 | 0 | 0 | 0 | For |
| First Trust | 178,135 | 0 | 0 | 0 | For |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 159,467 | 0 | 0 | 0 | For |
| Equitable | 157,755 | 0 | 0 | 0 | For |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 82,062 | 0 | 0 | 0 | For |
| Brighthouse | 76,036 | 0 | 0 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 67,170 | 0 | 0 | 0 | For |
| John Hancock | 60,959 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,674 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,311 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 43,636 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
93% Approved · of votes cast
Prior year: 93.2% for (May 29, 2025 meeting) ▼ 0.3 pts
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.
Spyre Therapeutics, Inc.’s own tally for this item (“2. On a non-binding, advisory basis, the compensation of the Company's named executive officers”): 62,075,459 for, 4,760,373 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,602,018 | 2,682 | 0 | 0 | For |
| Capital Group | 0 | 2,412,693 | 0 | 0 | Against |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 658,327 | 269 | 0 | 0 | For |
| Charles Schwab | 0 | 561,767 | 0 | 0 | Against |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 414,759 | 0 | 0 | 0 | For |
| Victory Capital | 326,801 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 318,219 | 0 | 0 | 0 | For |
| First Trust | 178,135 | 0 | 0 | 0 | For |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 159,467 | 0 | 0 | 0 | For |
| Equitable | 157,755 | 0 | 0 | 0 | For |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 82,062 | 0 | 0 | 0 | For |
| Brighthouse | 76,036 | 0 | 0 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 67,170 | 0 | 0 | 0 | For |
| John Hancock | 60,959 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,674 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,311 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 43,636 | 0 | 0 | 0 | For |
Fund voting reports, all 67 managers: 20,419,744 for, 3,077,031 against, 3,558 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 11,224,215 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 4,191,364 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 4,018,101 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 3,685,448 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 2,587,491 | 0 | 0 | 0 | For |
| Capital Group | 0 | 2,412,693 | 0 | 0 | Against |
| Commodore Capital LP | 1,806,463 | 0 | 0 | 0 | For |
| State Street | 1,702,478 | 10,432 | 0 | 0 | For |
| T. Rowe Price | 1,700,504 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,666,378 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 1,621,620 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,593,687 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,499,662 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
| Wellington | 1,070,333 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 932,823 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 879,501 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 818,598 | 0 | 0 | 0 | For |
| BlackRock | 660,128 | 7,794 | 0 | 0 | For |
| Caligan Partners LP | 662,832 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 591,286 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 562,659 | 0 | 0 | Against |
| Vanguard | 543,011 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 518,054 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 456,582 | 0 | 0 | Against |
Institutional-manager reports, all 170 managers: 49,049,364 for, 4,290,166 against, 5,692 abstained, 696 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.9% for (May 29, 2025 meeting) ▲ 0.1 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.
Spyre Therapeutics, Inc.’s own tally for this item (“3. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 68,430,566 for, 670 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,604,701 | 0 | 0 | 0 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 658,596 | 0 | 0 | 0 | For |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 414,759 | 0 | 0 | 0 | For |
| Victory Capital | 326,801 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 318,219 | 0 | 0 | 0 | For |
| First Trust | 178,135 | 0 | 0 | 0 | For |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 159,467 | 0 | 0 | 0 | For |
| Equitable | 157,755 | 0 | 0 | 0 | For |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 82,062 | 0 | 0 | 0 | For |
| Brighthouse | 76,036 | 0 | 0 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 67,170 | 0 | 0 | 0 | For |
| John Hancock | 60,959 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,674 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,311 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 43,636 | 0 | 0 | 0 | For |
Fund voting reports, all 67 managers: 23,496,776 for, 3,558 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 1,456,231 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 78,839,858 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 11.88% |
| 2 | Vanguard | 4.57% |
| 3 | Capital Group | 3.06% |
| 4 | BlackRock | 2.56% |
| 5 | T. Rowe Price | 1.60% |
| 6 | State Street | 0.84% |
| 7 | Charles Schwab | 0.71% |
| 8 | JPMorgan | 0.66% |
| 9 | DRIEHAUS MUTUAL FUNDS | 0.53% |
| 10 | Victory Capital | 0.41% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.24% |
| 2 | RTW INVESTMENTS, LP | 5.32% |
| 3 | Fairmount Funds Management LLC | 5.10% |
| 4 | Venrock Adviser, LLC | 4.67% |
| 5 | PERCEPTIVE ADVISORS LLC | 3.28% |
| 6 | Capital Group | 3.06% |
| 7 | Commodore Capital LP | 2.29% |
| 8 | State Street | 2.17% |
| 9 | T. Rowe Price | 2.16% |
| 10 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.11% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 11,781,024 | 14.94% | Form 13F, quarter ended March 31, 2026 |
| Peter Harwin | 9,016,702 | 11.44% | Schedule 13D, filed April 20, 2026 |
| Tomas Kiselak | 8,787,215 | 11.15% | Proxy statement (DEF 14A), table as of February 12, 2026 |
| Fairmount Healthcare Fund II L.P. | 8,271,021 | 10.49% | Proxy statement (DEF 14A), table as of February 12, 2026 |
| FMR LLC | 7,623,881 | 9.67% | Proxy statement (DEF 14A), table as of February 12, 2026 |
| BlackRock | 5,521,221 | 7.00% | Form 13F, quarter ended March 31, 2026 |
| Perceptive Advisors LLC | 4,319,496 | 5.48% | Schedule 13G, filed August 14, 2026 |
| RTW Investments, LP | 4,251,996 | 5.39% | Schedule 13G, filed August 14, 2026 |
| Vanguard Group | 4,035,074 | 5.12% | Form 13F, quarter ended March 31, 2026 |
| State Street | 2,607,031 | 3.31% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 78,839,858 shares outstanding, as reported by Spyre Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Spyre Therapeutics, Inc.'s shareholder meeting held May 27, 2026, in the 2025-2026 proxy season, 220 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,672 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — Spyre Therapeutics, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Spyre Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Spyre Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Spyre Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Spyre Therapeutics (SYRE) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/spyre-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.